SINOVAC Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

BEIJING, November 18, 2025--Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that on November 12, 2025, it received a delisting determination letter (the "Staff Determination") from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, unless the Company timely requests a hearing before the Nasdaq Hearing Panel, which the Company intends to do, t